CytoMed Therapeutics Limited reports developments in cell-based immunotherapies for cancer as a Singapore-based clinical-stage biopharmaceutical company. Its updates center on donor-derived allogeneic programs, including CAR γδ T cell therapies, iPSC-derived γδ NKT cell therapies, and γδ T cell product candidates such as CTM-N2D and CTM-GDT for blood and solid tumors.
Recurring news also covers clinical and regulatory disclosures, preclinical research publications, hospital and research collaborations, and the expansion of cord blood-derived Natural Killer cell work through LongevityBank and its licensed cord blood bank assets in Malaysia. Company communications include subsidiary investments, international expansion initiatives, shareholder ownership updates, and responses to public claims about its programs and operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.